Related Experiment Videos
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma
Abstract:
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of Dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in 28 patients with advanced malignant melanoma, none of whom had received prior cytotoxic chemotherapy. 27 of 28 patients were ECOG performance status 0 or 1. Mitoxantrone was administered at a dose of 12 mg/M2 as a 30-45 minute intravenous infusion repeated every 3 weeks as toxicity and response permitted. Dose limiting toxicity was myelosuppression. No cardiotoxicity was encountered in this study. In this optimal group of patients, only one partial response to Mitoxantrone was observed. At this dose and schedule, Mitoxantrone has no clinically worthwhile activity against malignant melanomas.
Insights
Dihydroxyanthracenedione (Mitoxantrone) showed limited efficacy in advanced malignant melanoma patients. The phase II trial revealed minimal response rates and dose-limiting myelosuppression, indicating no significant clinical benefit.
Area of Science:
- Medical Oncology
- Clinical Pharmacology
- Dermatology
Background:
- Advanced malignant melanoma remains a challenging cancer with limited treatment options.
- The Eastern Cooperative Oncology Group (ECOG) investigated novel chemotherapeutic agents for melanoma.
- Dihydroxyanthracenedione (Mitoxantrone) is an anthracenedione derivative with known cytotoxic properties.
Purpose of the Study:
- To evaluate the efficacy and safety of Dihydroxyanthracenedione (Mitoxantrone) in patients with advanced malignant melanoma.
- To determine the dose-limiting toxicities and response rates of Mitoxantrone in this patient population.
- To assess the clinical utility of Mitoxantrone as a treatment for advanced malignant melanoma.
Main Methods:
- A phase II clinical trial was conducted by the ECOG involving 28 treatment-naive patients.
- Mitoxantrone was administered intravenously at a dose of 12 mg/M2 every 3 weeks.
- Patient response, toxicity (including myelosuppression and cardiotoxicity), and performance status were closely monitored.
Main Results:
- Only one partial response was observed among the 28 patients.
- The dose-limiting toxicity identified was myelosuppression.
- No instances of cardiotoxicity were reported during the study.
- The majority of patients (27/28) had an ECOG performance status of 0 or 1.
Conclusions:
- At the tested dose and schedule, Mitoxantrone demonstrated no clinically significant activity against advanced malignant melanoma.
- Myelosuppression was the primary dose-limiting toxicity, whereas cardiotoxicity was not observed.
- Further investigation into Mitoxantrone for malignant melanoma is not recommended based on these findings.